Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort

Holz, Olaf; Waschki, Benjamin; Watz, Henrik; Kirsten, Anne; Abdo, Mustafa; Pedersen, Frauke; Weckmann, Markus; Fuchs, Oliver; Dittrich, Anna-Maria; Hansen, Gesine; Kopp, Matthias; Rabe, Klaus F.; Hohlfeld, Jens M.; Bahmer, Thomas

doi:10.1183/13993003.02127-2020

Cited by 10 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors concluded that successful validation of breathomics is needed before it can be considered a standard tool for PM [ 31 ]. One year later, the ALLIANCE cohort study confirmed the negative results, stating, “Despite recent publications, we are not close to finding a clinically valuable breath volatile organic compounds biomarker for asthma or asthma phenotypes” [ 32 ].…”

Section: Omicsmentioning

confidence: 99%

The Present and Future of Allergen Immunotherapy in Personalized Medicine

Ridolo

Incorvaia

Heffler

et al. 2022

JPM

View full text Add to dashboard Cite

Allergic diseases are particularly suitable for personalized medicine, because they meet the needs for therapeutic success, which include a known molecular mechanism of the disease, a diagnostic tool for that disease and a treatment that blocks this mechanism. A range of tools is available for personalized allergy diagnosis, including molecular diagnostics, treatable traits and omics (i.e., proteomics, epigenomics, metabolomics, transcriptomics and breathomics), to predict patient response to therapies, detect biomarkers and mediators and assess disease control status. Such tools enhance allergen immunotherapy. Higher diagnostic accuracy results in a significant increase (based on a greater performance achieved with personalized treatment) in efficacy, further increasing the known and unique characteristics of a treatment designed to work on allergy causes.

show abstract

Section: Omicsmentioning

confidence: 99%

The Present and Future of Allergen Immunotherapy in Personalized Medicine

Ridolo

Incorvaia

Heffler

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…Brinkman et al have also illustrated differences in exhaled volatiles such as methanol, acetonitrile, and bicyclooctan-1-ol, 4-methyl in patients with loss of asthma control compared with the recovery period (111). On the contrary, the results of the ALLIANCE study failed to show differences in exhaled VOCs and inflammatory markers in asthmatic patients (118). Although further work is required to validate these preliminary findings, several systematic reviews suggest the large potential for the breathomics biomarker approach (112).…”

Section: Proteomic/metabolomicsmentioning

confidence: 99%

Recent insights in the role of biomarkers in severe asthma management

et al. 2022

View full text Add to dashboard Cite

Contemporary asthma management requires a proactive and individualized approach, combining precision diagnosis and personalized treatment. The introduction of biologic therapies for severe asthma to everyday clinical practice, increases the need for specific patient selection, prediction of outcomes and monitoring of these costly and long-lasting therapies. Several biomarkers have been used in asthma in disease identification, prediction of asthma severity and prognosis, and response to treatment. Novel advances in the area of personalized medicine regarding disease phenotyping and endotyping, encompass the development and application of reliable biomarkers, accurately quantified using robust and reproducible methods. The availability of powerful omics technologies, together with integrated and network-based genome data analysis, and microbiota changes quantified in serum, body fluids and exhaled air, will lead to a better classification of distinct phenotypes or endotypes. Herein, in this review we discuss on currently used and novel biomarkers for the diagnosis and treatment of asthma.

show abstract

“… 74 Further work to validate these early findings is needed but initial systematic reviews suggest promise to this potential VOC-based biomarker approach. 75 …”

Section: Biomarkers That Support Asthma Managementmentioning

confidence: 99%

“…74 Further work to validate these early findings is needed but initial systematic reviews suggest promise to this potential VOC-based biomarker approach. 75 conventional markers. 76 Urinary LTE 4 has also shown potential as a marker for AERD.…”

Section: Exhaled Volatile Organic Compoundsmentioning

confidence: 99%

Recent Insights into the Management of Inflammation in Asthma

Rupani¹,

Fong²,

Kyyaly³

et al. 2021

JIR

View full text Add to dashboard Cite

The present prevailing inflammatory paradigm in asthma is of T2-high inflammation orchestrated by key inflammatory cells like Type 2 helper lymphocytes, innate lymphoid cells group 2 and associated cytokines. Eosinophils are key components of this T2 inflammatory pathway and have become key therapeutic targets. Real-world evidence on the predominant T2-high nature of severe asthma is emerging. Various inflammatory biomarkers have been adopted in clinical practice to aid asthma characterization including airway measures such as bronchoscopic biopsy and lavage, induced sputum analysis, and fractional exhaled nitric oxide. Blood measures like eosinophil counts have also gained widespread usage and multicomponent algorithms combining different parameters are now appearing. There is also growing interest in potential future biomarkers including exhaled volatile organic compounds, micro RNAs and urinary biomarkers. Additionally, there is a growing realisation that asthma is a heterogeneous state with numerous phenotypes and associated treatable traits. These may show particular inflammatory patterns and merit-specific management approaches that could improve asthma patient outcomes. Inhaled corticosteroids (ICS) remain the mainstay of asthma management but their use earlier in the course of disease is being advocated. Recent evidence suggests potential roles for ICS in combination with long-acting beta-agonists (LABA) for as needed use in mild asthma whilst maintenance and reliever therapy regimes have gained widespread acceptance. Other anti-inflammatory strategies including ultra-fine particle ICS, leukotriene receptor antagonists and macrolide antibiotics may show efficacy in particular phenotypes too. Monoclonal antibody biologic therapies have recently entered clinical practice with significant impacts on asthma outcomes. Understanding of the efficacy and use of those agents is becoming clearer with a growing body of real-world evidence as is their potential applicability to other treatable comorbid traits. In conclusion, the evolving understanding of T2 driven inflammation alongside a treatable traits disease model is enhancing therapeutic approaches to address inflammation in asthma.

show abstract

Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort

Cited by 10 publications

References 16 publications

The Present and Future of Allergen Immunotherapy in Personalized Medicine

The Present and Future of Allergen Immunotherapy in Personalized Medicine

Recent insights in the role of biomarkers in severe asthma management

Recent Insights into the Management of Inflammation in Asthma

Contact Info

Product

Resources

About